Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Empagliflozin
Drug ID BADD_D00765
Description Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.[A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.[L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects.[A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014.[A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Indications and Usage Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Marketing Status Prescription
ATC Code A10BK03
DrugBank ID DB09038
KEGG ID D10459
MeSH ID C570240
PubChem ID 11949646
TTD Drug ID D06ALD
NDC Product Code 12714-201; 71796-001; 65727-085; 49629-033; 76072-1015; 0597-0152; 49629-034; 62756-159; 0597-0153; 55154-0412; 71610-177; 50090-4384; 59651-179; 50090-4492; 70518-2447; 46708-903; 42765-016; 67835-0024; 55154-0411; 69766-036; 69037-0029; 69766-052; 70518-1986
Synonyms empagliflozin | 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene | BI 10773 | BI10773 | BI-10773 | Jardiance
Chemical Information
Molecular Formula C23H27ClO7
CAS Registry Number 864070-44-0
SMILES C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hemiparesis17.01.04.001--
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatic steatosis09.01.07.003; 14.08.04.0050.001123%Not Available
Hepatocellular injury09.01.07.008--Not Available
Herpes zoster23.09.03.002; 11.05.02.003--
Hip fracture15.08.03.001; 12.04.01.001--
Humerus fracture15.08.03.008; 12.04.01.0090.000749%Not Available
Hydrocephalus17.07.01.0010.000749%
Hypercalcaemia14.04.01.003; 05.04.01.0020.001497%
Hyperglycaemia05.06.02.002; 14.06.02.0020.009732%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.005615%
Hypernatraemia14.05.04.0010.001123%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.001--Not Available
Hyperthyroidism14.11.01.011; 05.02.02.001--
Hyperventilation22.02.01.006; 19.01.02.0040.002246%Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypoglycaemia05.06.03.001; 14.06.03.0010.007112%
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Hypovolaemia14.05.05.0020.004866%Not Available
Incontinence17.05.01.006; 07.01.06.011; 20.02.02.0040.002994%Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.0020.002441%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 17 Pages